The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models

In the present study, we investigated the activity of XL388, a novel mammalian target of rapamycin (mTOR) complex 1/2 (mTORC1/2) dual inhibitor, in preclinical osteosarcoma (OS) models. XL388 was cytotoxic, cytostatic and pro-apoptotic to multiple established OS cell lines and primary human OS cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yun-Rong, Zhou, Xiao-zhong, Zhu, Lun-qing, Yao, Chen, Fang, Jian-Feng, Zhou, Feng, Deng, Xiong-Wei, Zhang, Yun-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226526/
https://www.ncbi.nlm.nih.gov/pubmed/27385099
http://dx.doi.org/10.18632/oncotarget.10389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226526/
https://www.ncbi.nlm.nih.gov/pubmed/27385099
http://dx.doi.org/10.18632/oncotarget.10389

Ejemplares similares